共 257 条
[1]
Burstein HJ(2010)American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer J Clin Oncol 28 3784-3796
[2]
Prestrud AA(2015)Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials Lancet 386 1341-1352
[3]
Seidenfeld J(2012)Predictors of aromatase inhibitor discontinuation due to treatment-emergent symptoms in early-stage breast cancer J Clin Oncol 30 936-942
[4]
Anderson H(2005)Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation Arthritis Rheum 52 2594-2598
[5]
Buchholz TA(2002)Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study J Clin Oncol 20 751-757
[6]
Davidson NE(1998)In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients Clin Cancer Res 4 2089-2093
[7]
Gelmon KE(1996)Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer Br J Cancer 74 1286-1291
[8]
Giordano SH(2014)Interpreting plasma estrogen levels in breast cancer: caution needed J Clin Oncol 14 1396-1400
[9]
Hudis CA(2005)Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations J Steroid Biochem Mol Biol 95 75-81
[10]
Malin J(2007)Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomark Prev 16 1713-1719